Medexus Pharmaceuticals Inc. · TSX:MDP
Medexus Pharmaceuticals — Q1 FY2027 Earnings Presentation
17 slides from Medexus Pharmaceuticals's earnings presentation, August 2026
Slide 1: Medexus Pharmaceuticals Investor Presentation
TSX: MDP | OTCQX: MEDXF Ken d’Entremont, CEO Brendon Buschman, CFO
Slide 2: Important Notes
Important Notes Go to the latest Medexus MD&A or AIF for full disclaimers Cautionary Note This presentation has been prepared by the management of Medexus Pharmaceuticals Inc. (“Medexus“ or the “Company”) for informational purposes based on the Company’s public disclosure. The sole purpose of this p
Slide 3: Key Highlights
Premier orphan drug and rare KEY HIGHLIGHTS disease US$99.3M US$11.6M pharmaceutical FY2026 Net Revenue(1) FY2026 Product–level net revenue from company 14 GRAFAPEX (1,4) Brands in Market Significant Improving lives one patient at a time 75% near-term ✓ Focused on innovative ✓ Growing through increa
Slide 4: Diversified Product Portfolio
Diversified Product Portfolio • Our portfolio features leading products that address a variety of diseases. • We provide innovative prescription and over the counter brands to patients and healthcare professionals, which we believe greatly enhances quality of life. • We are focused on strengthening
Slide 5: Proven Business Model
Proven Business Model • Medexus seeks to license or acquire products to address essential needs of patients and health care partners, leveraging our established North American sales force and infrastructure across a growing product portfolio. • We closely monitor a robust pipeline of opportunities t
Slide 6: North American Commercial Platform In Place
Strong Commercial North American Commercial Commercial • • US$99.3M net revenue (FY2026) Established on-market portfolio Platform In Place Platform • $100M+ product-level net revenue from GRAFAPEX(1) within 5 years after launch. Medexus has built a • Generates meaningful operating cash flow(2) Field
Slide 7: GRAFAPEX (Treosulfan)
GRAFAPEX (Treosulfan) GRAFAPEX will drive significant net revenue and operating cash flow growth Net Revenue Potential First and only FDA-approved conditioning regimen for allogeneic hematopoietic stem cell transplantation, or “allo-HSCT”, to be used in combination with fludarabine, in eligible pati
Slide 8: Trecondyv (Treosulfan)
Trecondyv (Treosulfan) Treosulfan successful launch and rapid growth in Canada Ex-Factory $ Sales by Fiscal Yeare du Treosulfan was approved by Health Canada in June 2021, graphique and Medexus commercially launched treosulfan in $2500 000 Initiation of Canada under the brand name Trecondyv® in reim
Slide 9: Canadian Retrospective Study
Canadian Retrospective Study Princess Margaret hospital study shows a 56% lower risk/hazard of all-cause mortality* after 2 years with treosulfan- over busulfan-based conditioning in HSCT for patients with MDS, as well as other positive findings, all generally consistent with the results from the pi
Slide 10: Building Value Across the allo-HSCT Continuum
Building Value Across the allo-HSCT Continuum Two assets today. Integrated opportunities to improve outcomes across the entire patient journey. (2) (1) 1. Medexus Pharmaceuticals Inc. ho lds exclusive commercial ri ghts to UM171 Cell Therapy in Canada under June 2026 agreements w ith ExCell Thera an
Slide 11: IXINITY
IXINITY ® Delivering Long-Term Stability Medexus holds Global Rights to IXINITY® Currently indicated in adults and children with hemophilia B for control & prevention >$1 Billion* current US market with concentrated of bleeding episodes & for perioperative prescriber base. management. 4,000-5,000 to
Slide 12: Rasuvo / Metoject
Rasuvo® / Metoject Ma rk et Le a din g Pr odu c t Strong Market Position AutoPen Monthly TRX Unique formulation of methotrexate 9,000 7,452 8,000 7,103 Autoinjector designed to treat rheumatoid arthritis and other 7,000 auto immune disease. 6,000 7,015 Rasuvo has exclusive or advantaged status with
Slide 13: Selected Financial Results
Selected Financial Results All figures in US$M Fiscal Q1 Fiscal Year Net Revenue (US$M) (except multiples) $108.1 $113.1 2027 2026 2026 2025 $120 5 Year CAGR = 4% $108.3 $99.3 $100 $79.7 $76.7 Net Revenue $28.6 $24.6 $99.3 $108.3 $80 $60 Adjusted EBITDA(1) $4.7 $3.4 $16.5 $20.2 $40 $20 $0 Operating
Slide 14: Capital Structure
Capital Structure ( $ US D ) EV Calculation(1) Credit Facility Provides Significant Flexibility Share Price (at August 14, 2026) C$5.34/ US$3.83 Shares Outstanding (2) 31.4M • US$21 million term loan facility Equity Market Capitalization (at August 14, 2026) $120.4M • US$5 million revolving loan fac
Slide 15: Key Investment Highlights
Key Investment Highlights Positioned to deliver near-term and long-term company value Diversified, durable, portfolio currently generating US$103.3M(1) in net revenue, with positive Adj. EBITDA(2) Executing on significant year over year net revenue and Adj. EBITDA(2) growth strategy with the commerc
Slide 16: Company Contact
Company Contact Ken d’Entremont, CEO Phone: 905 676 0003 Email: Ken.Dentremont@medexus.com Brendon Buschman, CFO Phone: 416 577 6216 Email: Brendon.Buschman@medexus.com Investor Relations Frank Candido Direct Financial Strategies and Communication Inc. Phone: 514 969 5530 Email: Frank.Candido@direct
Slide 17: Important Notes
Important Notes See Medexus’s latest MD&A for more information Non-GAAP measures Company management uses, and this presentation refers to, non-GAAP measures, meaning financial measures that are not recognized under IFRS and do not have a standard meaning prescribed by GAAP in accordance with IFRS or
Medexus Pharmaceuticals — Q1 FY2027 Earnings Presentation on 6ix